Omalizumab

Omalizumab C화학적 특성, 용도, 생산

용도

Treatment of atopic disease (asthma; rhinitis) (monoclonal antibody).

Mechanism of action

Additional amino acid sequences have been incorporated into the antibody so that a humanized product resulted that only differs by 5% nonhuman amino acid residues. In vitro, omalizumab has been shown to complex with free IgE, forming trimers consisting of a 2:1 complex of IgE to omalizumab or a 1:2 complex of IgE to omalizumab. In addition, larger complexes also are formed, consisting of a 3:3 ratio of each. Omalizumab does not bind to IgE already bound to mast cells and, therefore, does not cause the degranulation that might be expected from such interaction. Thus, omalizumab effectively neutralizes free IgE and, aside from the obvious decrease of available IgE, also causes the down-regulation of FcεRI receptors on the mast cell surface, resulting in a decrease of IgE bound to the mast cell.

Pharmacokinetics

The bioavailability after subcutaneous administration is 62%, with slow absorption resulting in peak serum levels in 7 to 8 days from a single dose. Steady-state plasma concentration is reached in 14 to 29 days with multiple dosing regimens. The elimination of omalizumab is not clearly understood; however, studies have determined that intact IgE is excreted via the bile and that omalizumab:IgE complexes are cleared faster than uncomplexed omalizumab and slower than free IgE. This means that over time, total IgE concentrations (free and complexed IgE) increase, because the complex is cleared more slowly. The metabolism of omalizumab is not known, and the clearance of the complex is similar to the liver elimination of another immunoglobulin, IgG. The reticuloendothelial system degrades IgG, and it is believed that the same process occurs for the omalizumab:IgE complex.

Clinical Use

The clinical role for omalizumab is in the treatment of allergic asthma. It is approved for the treatment of adults and adolescents 12 years of age and older whose symptoms are not controlled with inhaled glucocorticoids and who have a positive skin test for airborne allergens.

Omalizumab 준비 용품 및 원자재

원자재

준비 용품

Omalizumab 공급 업체

공급자	전화	이메일	국가	제품 수	이점
Shanghai Minbiotech Co., Ltd.	+8617315815539	sales@minbiotech.com	CHINA	129	58
Hubei Ipure Biology Co., Ltd	+8613367258412	ada@ipurechemical.com	China	10326	58
HONG KONG IPURE BIOLOGY CO.,LIMITED	86 18062405514 18062405514	ada@ipurechemical.com	CHINA	3465	58
AFINE CHEMICALS LIMITED	0571-85134551	info@afinechem.com	CHINA	15377	58
Baoji Guokang Healthchem co.,ltd	+8615604608665 15604608665	dominicguo@gk-bio.com	CHINA	9427	58
Hefei Hirisun Pharmatech Co., Ltd	+8615056975894	shawn@hirisunpharm.com	CHINA	9923	58
Hangzhou Huarong Pharm Co., Ltd.	571-86758373 +8613588754946	sales@huarongpharm.com	CHINA	3149	58
Nantong HI-FUTURE Biology Co., Ltd.	+undefined18051384581	sales@chemhifuture.com	China	3136	58
TargetMol Chemicals Inc.	+1-781-999-5354	support@targetmol.com	United States	19973	58
LEAPCHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	43348	58

Omalizumab 관련 검색: